

TIN-0017

IN THE CLAIMS

Claims 1-10 (canceled)

Claim 11 (currently amended): A method of treating sinusitis and rhinitis in a human or an animal in need thereof, the method comprising:

administering to a nasal passageway of the human or the animal a composition comprising alpha-hydroxypropionic acid and a pharmaceutically acceptable vehicle, wherein the alpha-hydroxypropionic acid is in a concentration of 0.2- 4 vol.% based on the volume of the acceptable pharmaceutical vehicle; and

wherein the sinusitis and rhinitis are caused by a bacterial organism or a fungal organism.

Claim 12 (previously presented): The method as claimed in claim 11, wherein the pharmaceutically acceptable vehicle comprises 1,2,3-propanetriol, 1,2-propanediol, serum, or a mixture consisting of at least two of the foregoing.

Claims 13-16 (canceled)

Claim 17 (previously presented): The method as claimed in claim 11, wherein the composition is used as to exfoliate the mucosa of the nasal passages.

Claims 18 and 19 (canceled)

Claim 20 (previously presented): The method as claimed in claim 12, wherein the pharmaceutically acceptable vehicle is 1,2,3-propanetriol.

Claim 21 (previously presented): The method as claimed in claim 12, wherein the pharmaceutically acceptable vehicle is serum.

TIN-0017

Claim 22 (previously presented): The method as claimed in claim 12, wherein the pharmaceutically acceptable vehicle is 1,2-propanediol.

Claim 23 (canceled)

Claim 24 (previously presented): The method as claimed in claim 11, wherein the composition is placed into a pharmaceutically acceptable form consisting of drops, a spray, and a fine powder.

Claims 25 and 26 (canceled)

Claim 27 (previously presented): The method of Claim 22, wherein the composition has a ratio of the alpha-hydroxypropionic acid to the 1,2-propanediol of 1:1 to 1:5.

Claim 28 (currently amended): A method of treating an upper respiratory disorder selected from sinusitis and rhinitis in a human or an animal in need thereof, the method comprising:

administering to a nasal passageway of the human or the animal a composition comprising:

alpha-hydroxypropionic acid; and

a pharmaceutically acceptable vehicle comprising 1,2,3-propanetriol, 1,2-propanediol, [a] serum [of 1,2-propanediol], or a mixture[s] of at least two of the foregoing vehicles;

wherein the alpha-hydroxypropionic acid is in a concentration of 0.2- 4 vol.% based on the volume of the acceptable pharmaceutical vehicle; and.

wherein the sinusitis and rhinitis are caused by a bacterial organism or a fungal organism.

Claim 29 (previously presented): The method of Claim 28, wherein the upper respiratory disorder is sinusitis.

TIN-0017

Claim 30 (currently amended): A method of treating an upper respiratory disorder selected from sinusitis and rhinitis caused by bacteria in a human or an animal in need thereof, the method comprising:

administering to a nasal passageway of the human or the animal a composition comprising alpha-hydroxypropionic acid and a pharmaceutically acceptable vehicle, wherein the alpha-hydroxypropionic acid is in a concentration of 0.2- 4 vol.% based on the volume of the acceptable pharmaceutical vehicle.

Claim 31 (currently amended): The method of Claim 30, wherein the pharmaceutically acceptable vehicle comprises 1,2,3-propanetriol, 1,2-propanediol, [a] serum [of 1,2-propanediol], or a [balanced] mixture[s] of at least two of the foregoing vehicles.

Claim 32 (previously presented): The method of Claim 30, wherein the upper respiratory disorder is sinusitis.